Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will Pharma End Up Paying For The Infrastructure Bill?

Executive Summary

Or can industry thread the donut hole and prevent government price negotiations from becoming a part of the legislative tsunami?

You may also be interested in...



The Rebate Rule: US Pricing Proposal Becomes Congressional Piggy Bank

A policy eliminating rebates in the Medicare Part D program will be delayed until Jan. 1, 2026 – and is very likely to be repealed altogether. If that staves off more draconian reforms, the biopharma industry will celebrate.

A Presidential Punt On Drug Pricing

White House confirms that it will not be pushing major drug pricing provisions to help pay for its next multi-trillion dollar legislative proposal. That sounds like good news for industry – but don’t pop the champagne just yet.

US Drug Pricing Bill’s Prospects Will Be Shaped By Whether Public Worries More About Access Than Cost

HR 3 has been re-introduced, and some provisions may be attached to the White House’s infrastructure bill, but the government price negotiation system envisioned by the bill may fail – if industry can convince Congress to focus on access to medicines, not their cost.

Related Content

Topics

UsernamePublicRestriction

Register

PS144065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel